Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a serious life-threatening malignancy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. However, this therapy ju...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Zhong, Lei, Yang, Jiao, Cao, Zhixing, Chen, Xin, Hu, Yiguo, Li, Linli, Yang, Shengyong
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355060/
https://ncbi.nlm.nih.gov/pubmed/28086226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14597
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg